Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Aldeyra Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Aldeyra Therapeutics, Inc.’s stock price such as:

• Aldeyra Therapeutics, Inc.’s current stock price and volume
• Why Aldeyra Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for ALDX from analysts
• ALDX’s stock price momentum as measured by its relative strength

About Aldeyra Therapeutics, Inc. (ALDX)

Before we jump into Aldeyra Therapeutics, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platforms, including ADX 248, ADX 246, and other novel RASP modulators for the treatment of various diseases associated with RASP. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.

Want to learn more about Aldeyra Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Aldeyra Therapeutics, Inc..

Aldeyra Therapeutics, Inc.’s Stock Price as of Market Close

As of June 11, 2026, 4:00 PM, CST, Aldeyra Therapeutics, Inc.’s stock price was $1.710.

Aldeyra Therapeutics, Inc. is up 1.18% from its previous closing price of $1.690.

During the last market session, Aldeyra Therapeutics, Inc.’s stock traded between $1.660 and $1.730. Currently, there are approximately 60.32 million shares outstanding for Aldeyra Therapeutics, Inc..

Aldeyra Therapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Aldeyra Therapeutics, Inc. Stock Price History

Aldeyra Therapeutics, Inc.’s (ALDX) price is currently down 2.29% so far this month.

During the month of June, Aldeyra Therapeutics, Inc.’s stock price has reached a high of $1.970 and a low of $1.580.

Over the last year, Aldeyra Therapeutics, Inc. has hit prices as high as $6.175 and as low as $1.070. Year to date, Aldeyra Therapeutics, Inc.’s stock is down 66.99%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Aldeyra Therapeutics, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

One of the most common factors that can drastically impact a stock’s price is analyst upgrades and downgrades. When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. However, as of June 10, 2026,, no analysts have changed their rating of Aldeyra Therapeutics, Inc.’s stock over the last month.

Additionally, you'll want to evaluate Aldeyra Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Aldeyra Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Aldeyra Therapeutics, Inc. (ALDX) by visiting AAII Stock Evaluator.

Relative Price Strength of Aldeyra Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of June 10, 2026, Aldeyra Therapeutics, Inc. has a weighted four-quarter relative price strength of -12.00%, which translates to a Momentum Score of 21 and is considered to be Weak.

Want to learn more about how Aldeyra Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Aldeyra Therapeutics, Inc. Stock Price: Bottom Line

As of June 11, 2026, Aldeyra Therapeutics, Inc.’s stock price is $1.710, which is up 1.18% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Aldeyra Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.